• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » What is the Minimum Effective Dose of OROS Methylphenidate for Adolescents?

What is the Minimum Effective Dose of OROS Methylphenidate for Adolescents?

September 1, 2010
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information
Editor-in-Chief, Caroline Fisher, PhD, MD

Subject:
ADHD

Short Description:
What is the Minimum Effective Dose of OROS Methylphenidate for Adolescents?

Background:
Dosing stimulants is never easy. There are various rules of thumb—for example, 0.5 mg/kg for amphetamine preparations and 1 mg/kg for methylphenidate preparations—but these have not been empirically validated. Ortho-McNeil Janssen funded a recent study designed to define the optimal dose of their medication OROS methylphenidate (Concerta, a controlled release MPH that lasts for 10 to 12 hours) for adolescents. Two hundred and twenty adolescents ages 13 to 18 with ADHD were enrolled in a four-week, open label trial examining escalating dose-titration of OROS MPH to determine minimum dose required for response (defined as a 30% or greater reduction in baseline ADHD Rating Scale score and a rating of “good” or “excellent” on the Global Assessment of Effectiveness Scale). All participants started with 18 mg of OROS for one week. Nonresponders had their doses raised in weekly increments (from 18 mg to 36 mg to 54 mg to 72 mg) until a minimal response was achieved, or they reached the maximum dose for this trial (72 mg). About two thirds (65.4%) of patients required a dose of 54 mg or higher to meet criterion for improvement (27% responded to 54 mg dose; another 38% needed 72 mg to reach response). Eleven patients did not meet the requirements for improvement even at the 72 mg dose. Was there any way to predict which kids would need higher doses? Those with more severe ADHD symptoms at onset required higher doses, but neither age nor height nor weight were significant factors in predicting effective dose. As expected, adolescents required a higher absolute dose of OROS than children to achieve results. However, when the dose is adjusted for weight, adolescents actually need a slightly lower dose than children (0.84 mg/kg, compared to 1.1 mg/kg for younger kids). Fifty-seven percent of participants reported one or more drug related adverse events. The most common of these were anorexia (ranging from 6% to 10% dependent on dose) and headache (ranging from 9% to 11% depending dose) (Newcorn JH et al., J Child Adolesc Psychopharm 2010;20(3):187–196).

TCPR's Take:
While this study was clearly designed to showcase the manufacturer’s product, it is still a useful study clinically, because OROS MPH is used by so many psychiatrists and dosing guidance is always welcome. The authors conclude that a target dose of 1 mg/kg is reasonable for most adolescents.

Child Psychiatry
KEYWORDS adhd child-psychiatry
    www.thecarlatreport.com
    Issue Date: September 1, 2010
    SUBSCRIBE NOW
    Table Of Contents
    Book Reviews
    Assessing Depression in Adolescents
    What is the Minimum Effective Dose of OROS Methylphenidate for Adolescents?
    Trends in Medication Use for Children with Insomnia
    Treating Depressed Adolescents Who Have Attempted Suicide: Results of the TASA Trial
    Editor’s Perspective: Do Antidepressants Work in Kids?
    Featured Book
    • CMFB2e_Cover.png

      Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

      All the important facts covering child and adolescent psychopharmacology.
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto17326101.jpg
      Child Psychiatry

      Recognizing Developmental Trauma Disorder in Children and Adolescents

      Whether due to COVID, conflict, climate, or common car crashes, children often lose their caregiver at the same time they experience trauma. Our podcast with Julian Ford will...

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.